At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating carboplatin, Nab-paclitaxel, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
The purpose of this research study is to learn more about whether the combination of drugs carboplatin, Abraxane and Avastin helps treat non-small cell lung cancer (NSCLC). One of the standard treatments for advanced NSCLC is the combination of the drugs carboplatin, paclitaxel and Avastin. Paclitaxel can be associated with severe side effects that may make the treatment difficult to tolerate. Some of these side effects are caused by the solution used to dissolve paclitaxel before it can be administered. Abraxane is a different form of paclitaxel that does not need to be dissolved by this solution. Abraxane is approved for the treatment of breast cancer but is not approved to treat NSCLC. We will also be trying to learn more about how the drug Avastin may work to treat cancer.
Study Details
Timeline
Interventions
Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
IV infusion